Concepedia

David A. Sallman

DA

119

Publications

6.4K

Citations

43

H-Index

2006

Active since

Affiliations

Moffitt Cancer Center(Current)

The University of Texas MD Anderson Cancer Center

University of South Florida

Dana-Farber Cancer Institute

Cleveland Clinic

David A. Sallman is an author at Moffitt Cancer Center specializing in medicine, hematology, and oncology.

ORCID

Top concepts

Publications per year

2006–2025

119

Publications

119

Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes

David A. Sallman, Amy E. DeZern, Guillermo Garcia‐Manero et al. · Journal of Clinical Oncology · 2021 · 436 citations · Full text

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

Ashley A. Basiorka, Kathy L. McGraw, Erika A. Eksioglu et al. · Blood · 2016 · 337 citations · Full text

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study

Nancy Gillis, Markus Ball, Qing Zhang et al. · The Lancet Oncology · 2016 · 307 citations · Full text

, , +9

Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

Thomas Cluzeau, Marie Sébert, Ramy Rahmé et al. · Journal of Clinical Oncology · 2021 · 256 citations · Full text

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

Detlef Haase, Kristen E. Stevenson, Donna Neuberg et al. · Leukemia · 2019 · 252 citations · Full text

Rows per page

1–5 of 119